Impact Events
MoreDate | Lead Company | Event | Type | Approval Change | Approval Likelihood |
---|---|---|---|---|---|
10/20/25 | Adlai Nortye Biopharma (ANL) | Buparlisib for Head and Neck Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
10/20/25 | Roche (RO) | Tecentriq for Bladder Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
10/20/25 | Perspective Therapeutics (CATX) | VMT-𝛼-NET for Neuroendocrine Tumors (NET) | Subscribers Only | Subscribers Only | Subscribers Only |
10/20/25 | Amgen (AMGN) | Bemarituzumab for Gastric Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
10/19/25 | Johnson & Johnson (JNJ) | Amivantamab SC for Head and Neck Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
MoreExpected Date Range | Lead Company | Drug | Expected Catalyst |
---|---|---|---|
01/31/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
01/31/2025 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |